Comprehensive meta-analysis of survival outcomes from two randomized multicenter trials in first-line advanced non-small cell lung cancer in patients treated with the novel investigational antitumor-enhancing and chemoprotective agent Tavocept

Frederick Hausheer, Stacey Bain, Michael Perry, Lingu Du, Yasuo Ohashi, Yutaka Ariyoshi, Masahiro Fukuolca

Research output: Contribution to journalArticle

Abstract

We performed a comprehensive meta-analysis of two recent, multicenter, randomized, and controlled trials of the investigational new drug Tavocept (vs. placebo or no Tavocept) in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) who were treated with taxane plus cisplatin therapy. Significant improvements in overall and l-year survival were observed, which were most apparent in patients with the adenocarcinoma subtype. The results of this meta-analysis support the view that Tavocept combined with taxane plus cisplatin first-line therapy may result in significant increases in overall and i-year survival in patients with primary adenocarcinoma of the lung. The results of this systematic meta-analysis were used for the design and scientific justification of an international, double-blind, and placebo-controlled phase III confirmatory trial of Tavocept in patients with advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with taxane plus cisplatin using a primary endpoint of overall survival.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalAsia-Pacific Journal of Oncology and Hematology
Volume2
Issue number1
StatePublished - Feb 2010
Externally publishedYes

Keywords

  • Adenocarcinoma
  • Antitumor enhancement
  • BNP7787
  • Chemoprotection
  • Lung cancer
  • Meta-analysis
  • Survival
  • Tavocept

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Comprehensive meta-analysis of survival outcomes from two randomized multicenter trials in first-line advanced non-small cell lung cancer in patients treated with the novel investigational antitumor-enhancing and chemoprotective agent Tavocept'. Together they form a unique fingerprint.

Cite this